bioAffinity Technologies posts over 100% growth in CyPath Lung sales
bioAffinity Technologies reported sales of its CyPath Lung test for lung cancer increased more than 100% through the third quarter of 2026 compared to 2025. The number of ordering physicians increased by 89% in Q3 2026 compared to Q3 2025.